First clinical experience with endothelin receptor antagonist bosentan used in patients with pulmonary hypertension: results of a one-year study

AIM: To evaluate the efficiency and safety of long-term (12-month) treatment with the endothelin receptor antagonist bosentan (tracleer (Actelion, Switzerland)) in patients with pulmonary hypertension (PH)/MATERIAL AND METHODS: The prospective observational study enrolled 10 patients (8 with idiopat...

Full description

Bibliographic Details
Published in:Терапевтический архив
Main Authors: S N Avdeev, N A Tsareva, G V Nekliudova, A G Chuchalin
Format: Article
Language:Russian
Published: "Consilium Medicum" Publishing house 2013-03-01
Subjects:
pulmonary hypertension
endothelin receptor antagonists
bosentan
Online Access:https://ter-arkhiv.ru/0040-3660/article/view/31217

Internet

https://ter-arkhiv.ru/0040-3660/article/view/31217

Similar Items